12 June 2018 - Nearly two years after taking tremendous heat for the rising cost of EpiPens, pharmaceutical giant Mylan is making strides in the fast-growing market for biosimilars. 

Mylan won FDA approval last week for the first biosimilar product to Neulasta, a drug designed to help cancer patients reduce infection risk during chemotherapy. Mylan CEO Heather Bresch told "CBS This Morning" on Tuesday that its Neulasta biosimilar will translate to "significant savings" for patients. She also applauded President Trump's plan to lower the cost of drugs.

"We'll be launching our biosimilar to Neulasta in the coming weeks at a significant reduction. Double-digits reduction," Bresch said.

Read CBS News article